Evidence map›Paper›PMID 39921522›Full record

Trial reportLeukemia & lymphoma2025

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz, Paul A Hamlin, Youn H Kim, Ryan A Wilcox, Manish R Patel, Greg Coffey and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01994382 (A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01994382 phase1 / phase2completednot on this map

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

TypeinterventionalSponsorAlexion Pharmaceuticals, Inc.Ran2013 to 2020Enrolled260ConditionsFollicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL)ArmsCerdulatinib, Rituximab
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Review
  3. Review
  4. Novel agents and therapeutic advances in T cell lymphoma.International journal of hematology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Steven M HorwitzMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6399-2006
Tatyana A FeldmanJohn Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.ORCID 0000-0002-4458-2896
Jing Christine YeUniversity of Michigan, Ann Arbor, MI, USA.
Michael S KhodadoustStanford University School of Medicine, Palo Alto, CA, USA.ORCID 0000-0001-9061-7351
Javier MunozBanner MD Anderson Cancer Center, Gilbert, AZ, USA.ORCID 0000-0002-9060-8911
Paul A HamlinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9500-1804
Youn H KimStanford University School of Medicine, Palo Alto, CA, USA.ORCID 0000-0003-2686-5873
Ryan A WilcoxUniversity of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6420-0760
Manish R PatelFlorida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.ORCID 0000-0001-6836-2364
Greg CoffeyAlexion, AstraZeneca Rare Disease, Boston, MA, USA.ORCID 0009-0008-2566-3755
Alison InnesAlexion, AstraZeneca Rare Disease, Boston, MA, USA.
Andreas BetzAlexion, AstraZeneca Rare Disease, Boston, MA, USA.ORCID 0009-0001-6908-0948
Jaymes HollandAlexion, AstraZeneca Rare Disease, Boston, MA, USA.ORCID 0009-0004-0532-1740
Cristina B GuzmanAlexion, AstraZeneca Rare Disease, Boston, MA, USA.
Sonali M SmithUniversity of Chicago Medicine, Chicago, IL, USA.ORCID 0000-0002-9893-4949

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH],

Indexed as

Antineoplastic AgentsJanus Kinase InhibitorsLymphoma, T-Cell, PeripheralNeoplasm Recurrence, LocalProtein Kinase InhibitorsPyrimidinesAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRecurrenceSyk KinaseAntineoplastic AgentsJanus Kinase InhibitorsProtein Kinase InhibitorsPyrimidinesSyk Kinasedual spleen tyrosine kinase/janus kinase inhibitorPeripheral T-cell lymphomaphase-2 studyrelapsed/refractory

Identifiers

PMID39921522
PMCPMC12668183

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.